logo


Welcome to the website dedicated to the VAGUS scale©

The VAGUS measures the core dimensions of clinical insight into psychosis, including general illness awareness, symptom attribution, awareness of need for treatment, and awareness of negative consequences attributable to the illness. The VAGUS was designed to assess clinical insight in schizophrenia spectrum disorders, namely schizophrenia and schizoaffective disorder. The scale, however, can be used to assess clinical insight in any psychotic disorder, e.g. mood disorders with psychotic features, such as bipolar disorder or depression.

The VAGUS is the first insight into psychosis scale with both self-report and clinician-rated versions. It is easy to administer. The 10-item self-report (VAGUS-SR) and 5-item clinician-rated (VAGUS-CR) can be completed in less than 5 minutes. Both the VAGUS-SR and VAGUS-CR show good internal consistency, reliability and validity. Using a 10-point Likert scale for each item, the VAGUS has the capacity to detect small, temporally sensitive changes in insight, which is essential for intervention studies with neurostimulation or other rapidly acting interventions.

The VAGUS-SR and VAGUS-CR are available for download. Please see the terms of use below.

 


 

TERMS OF USE

VAGUS scale Copyright © is owned by the Centre for Addiction & Mental Health, (CAMH), Toronto, Canada, published 2014 (Canadian Copyright Registration No. 1108200; Registered October 8, 2013). Please read the paragraph below and click the ACCEPT button to acknowledge the terms and usage of www.vagusonline.com and the related VAGUS scale©. Thank you for your interest and support.

PERMISSION TO USE www.vagusonline.com and the related VAGUS scale© is as follows:


CLINICAL USE
• Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
VAGUS scale© may be used, reproduced, and distributed WITHOUT permission subject to the exception below for entities funded by a commercial entity or pharma. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma.
• Commercial Entity/Pharma:
VAGUS scale© may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.

 

EDUCATIONAL USE
• Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
VAGUS scale© may be used, reproduced, and distributed WITHOUT permission subject to the exception below for entities funded by a commercial entity or pharma. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma.
• Commercial Entity/Pharma:
VAGUS scale© may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.

 

RESEARCH USE
• Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
VAGUS scale© may be used, reproduced, and distributed only WITH prior written permission from CAMH. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma.
• Commercial Entity/Pharma sponsored research:
VAGUS scale© may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.

 

For more information, please contact: 
Dr. Philip Gerretsen, MD, FRCPC
info@vagusonline.com